FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average I	hurdon									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

											<u> </u>										
Name and Address of Reporting Person* Schenkein David P						2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Schenkem David I						AGIO]								X				10% C			
(Last) (First) (Middle)														X	Officer below)	er (give title Other (spe v) below)					
C/O AGIOS PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year)															
			o, mvc.		10/	02/20)17														
88 SIDNEY STREET						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable							
(Street)					- 4. 11	Amei	iumei	ii, Dale	oi Origii	iai Fiit	eu (Montin/D	ay/ rear)		Line)	iviuuai oi .	JohnivGrou	ıh Lıııı	g (Check A	pplicable		
CAMBR	IDGE M	A	02139												X Form filed by One Reporting Person						
					-												ore thar	n One Rep	orting		
(City)	(S	tate)	(Zip)												Persor	1					
		Tab	le I - N	on-Deriv	vative	Sec	uriti	ies Ac	quire	d, Di	sposed o	of, or Be	enefic	ially	Owned	ı					
Date			Date	Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a					s Illy	Form:	Direct Indirect	7. Nature of Indirect Beneficial Ownership			
							,		Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)		(,,(,,		(Instr. 4)		
Common stock 10/02				10/02/	2017				M ⁽¹⁾		6,000	A	\$0.3	025	6,0	00	D				
			10/02/	2017	╁			S ⁽²⁾		6,000	D	\$66.	76(3)	5 ⁽³⁾ 0		D					
Common	Stock			10/02/	2017	-			5(-)		0,000	1 1	Φ00.	/ 0 (3)	<u> </u>	,		D			
Common	stock														271,	772			See footnote ⁽⁴⁾		
Common stock															79,082		I		See footnote ⁽⁵⁾		
		1	able II	- Deriva	ative S	Secu	ritie	s Acq	uired,	Dis	posed of	, or Ben	eficia	ally (- Owned		J				
											converti										
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code (8)		tion of		6. Date Expirati (Month/	ion Da		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		E	B. Price of Derivative Gecurity Instr. 5)	9. Numbe derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	e Owners es Form: ally Direct (or Indir g (I) (Insti		Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	oer							
Stock option (right to	\$0.3025	10/02/2017			M ⁽¹⁾			6,000	(6)		08/12/2019	Common stock	6,00	00	\$0.00	112,6	56	D			

Explanation of Responses:

- 1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$66.21 to \$67.18. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 4. Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
- 5. Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- 6. This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on August 1, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

/s/ Andrew Hirsch, as Attorney in Fact for David Schenkein

10/04/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.